Venture Life Group PLC
LSE:VLG
Venture Life Group PLC
Venture Life Group Plc engages in the development, manufacture, and commercializing of products for the aging population. The company is headquartered in Bracknell, Berkshire and currently employs 119 full-time employees. The company went IPO on 2014-03-28. The firm is focused on developing, manufacturing and commercializing products for the global self-care market. The firm's segments include Brands, which includes sales of healthcare and skin care products under distribution agreements and direct to United Kingdom retailers, and Development and Manufacturing. Through its two Development and Manufacturing operations in Italy and Sweden, the Company also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. Its product portfolio includes the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
Venture Life Group Plc engages in the development, manufacture, and commercializing of products for the aging population. The company is headquartered in Bracknell, Berkshire and currently employs 119 full-time employees. The company went IPO on 2014-03-28. The firm is focused on developing, manufacturing and commercializing products for the global self-care market. The firm's segments include Brands, which includes sales of healthcare and skin care products under distribution agreements and direct to United Kingdom retailers, and Development and Manufacturing. Through its two Development and Manufacturing operations in Italy and Sweden, the Company also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. Its product portfolio includes the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
Revenue Growth: Group revenue rose 43% to GBP 15.4 million, with 12.5% organic growth, driven by both UK consumer brands and international markets.
Health & Her Acquisition: The Health & Her business contributed GBP 4 million in the first half, boosting reported growth and improving margins due to higher product profitability.
Margin Expansion: Gross margin increased to 43.1%, up from 41.2% last year, aided by the mix shift from higher-margin brands.
Marketing Investment: Marketing spend rose to 10.5% of group sales (14.5% on supported brands), targeting brand awareness and long-term revenue acceleration.
Cash Position & Firepower: Following the CDMO divestment, net cash was GBP 34 million at September end, with up to GBP 85 million available for acquisitions.
Brand Performance: Strong growth in women's health (Balance Activ up 24%) and Health & Her (up 35%), but energy management brands declined due to a temporary NHS ordering issue.
Strategic Refocus: The company completed its shift to a capital-light, brand-led model, divesting manufacturing and non-core brands to focus on high-margin categories.
Outlook: Management is confident in continued organic growth, margin improvement, and upcoming acquisitions, with a strong emphasis on innovation, digital, and international expansion.
